215 related articles for article (PubMed ID: 27063429)
1. [One year persistence of metformin monotherapy versus metformin/sitagliptin fixed dose combination].
Simonyi G; Ferenci T
Orv Hetil; 2016 Apr; 157(16):618-22. PubMed ID: 27063429
[TBL] [Abstract][Full Text] [Related]
2. [Ramipril plus amlodipine and lisinopril plus amlodipine fixed dose combinations and patient's adherence].
Simonyi G; Ferenci T
Orv Hetil; 2016 Jan; 157(1):30-4. PubMed ID: 26708684
[TBL] [Abstract][Full Text] [Related]
3. [One year adherence of ramipril versus ramipril/amlodipine fixed dose combination therapy in hypertension].
Simonyi G; Ferenci T
Orv Hetil; 2017 Oct; 158(42):1669-1673. PubMed ID: 29037057
[TBL] [Abstract][Full Text] [Related]
4. [One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy].
Simonyi G; Ferenci T
Orv Hetil; 2016 Mar; 157(11):425-9. PubMed ID: 26947091
[TBL] [Abstract][Full Text] [Related]
5. [Medication adherence with the fixed combination of ramipril and amlodipine].
Simonyi G; Ferenci T
Orv Hetil; 2014 Nov; 155(47):1882-8. PubMed ID: 25403283
[TBL] [Abstract][Full Text] [Related]
6. Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.
Bloomgarden ZT; Tunceli K; Liu J; Brodovicz KG; Mavros P; Engel SS; Radican L; Chen Y; Rajpathak S; Qiu Y; Brudi P; Fonseca V
J Diabetes; 2017 Jul; 9(7):677-688. PubMed ID: 27531167
[TBL] [Abstract][Full Text] [Related]
7. [Low persistence of simvastatin and ezetimibe fixed combination in the lipid lowering therapy].
Simonyi G; Ferenci T
Orv Hetil; 2015 Jan; 156(4):141-5. PubMed ID: 25597318
[TBL] [Abstract][Full Text] [Related]
8. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
[TBL] [Abstract][Full Text] [Related]
9. [One year persistence of free and fixed dose combinations of perindopril/amlodipine].
Simonyi G; Ferenci T; Medvegy M; Gasparics R; Finta E
Orv Hetil; 2017 Sep; 158(36):1421-1425. PubMed ID: 28868908
[TBL] [Abstract][Full Text] [Related]
10. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
12. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ
Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968
[TBL] [Abstract][Full Text] [Related]
14. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
Barner JC
Clin Ther; 2011 Sep; 33(9):1281-8. PubMed ID: 21840054
[TBL] [Abstract][Full Text] [Related]
15. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
16. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
17. Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy.
Inzucchi SE; Tunceli K; Qiu Y; Rajpathak S; Brodovicz KG; Engel SS; Mavros P; Radican L; Brudi P; Li Z; Fan CP; Hanna B; Tang J; Blonde L
Diabetes Obes Metab; 2015 Oct; 17(10):956-64. PubMed ID: 25962401
[TBL] [Abstract][Full Text] [Related]
18. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
19. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study.
Valensi P; de Pouvourville G; Benard N; Chanut-Vogel C; Kempf C; Eymard E; Moisan C; Dallongeville J
Diabetes Metab; 2015 Jun; 41(3):231-8. PubMed ID: 25976701
[TBL] [Abstract][Full Text] [Related]
20. [Cardiovascular safety of sitagliptin added to metformin in real world patients with type 2 diabetes].
Liu Z; Chen X; Zhao H; Zhan S; Sun F
Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Jun; 56(3):424-430. PubMed ID: 38864127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
